Geninus

지니너스 · 389030

Industrials Commercial Services · KOSDAQ

Small-cap

Market cap US$83.6M (₩115.4B)

Overview

Geninus is a biotech company that reads and interprets human genetic data to help drug developers find new medicine targets and to help clinicians detect cancer, using tools such as next-generation sequencing (a method of rapidly decoding DNA) and AI-powered digital pathology analysis.

Its customers include pharmaceutical companies, academic researchers, and clinical laboratories. Listed on KOSDAQ, Korea's tech-focused small-cap board, the company organises its business around three lines: software platforms for pharma drug discovery, genomic analysis solutions for researchers, and cancer diagnostic services such as its CancerSCAN and LiquidSCAN tests.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$7.6M

▲ +20952.8% YoY

Operating profit · FY2025

−US$8.5M

Loss widened

Net income · FY2025

−US$12.6M

Loss widened

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$5M(₩7B)	US$36.1K(₩49.8M)	US$7.6M(₩10.5B)
Operating profit	−US$7.3M(−₩10.1B)	−US$10K(−₩13.8M)	−US$8.5M(−₩11.7B)
Net income	−US$7M(−₩9.7B)	−US$10K(−₩13.8M)	−US$12.6M(−₩17.4B)

Revenue

FY2023US$5M
FY2024US$36.1K
FY2025US$7.6M

Operating profit

FY2023−US$7.3M
FY2024−US$10K
FY2025−US$8.5M

Net income

FY2023−US$7M
FY2024−US$10K
FY2025−US$12.6M

Key ratios (FY2025)

ROE

-190.9%

Debt/Eq

332.3%

Op. margin

-111.3%

Net margin

-165.7%

Rev. YoY

▲ +20952.8%

Why it matters

Geninus was spun off from the Samsung Genome Institute at Samsung Seoul Hospital, which is the origin of its proprietary bioinformatics database and analytical capabilities.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?